The clinically available PARP inhibitors (PARPis) olaparib, rucaparib, talazoparib, and niraparib operate by this mechanism and are frequently employed in cancers where HDR-deficiency is conferred by BRCA mutations. This evidence concerns the gene PARP1 and cancer.